OraSure Technologies, Inc.

319 articles with OraSure Technologies, Inc.

• OraSure’s OMNIgene®·ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2

  10/19/2020

  OraSure Technologies, Inc. announced its DNA Genotek subsidiary has received Emergency Use Authorization from the U.S. Food and Drug Administration for the use of DNA Genotek’s OMNIgene®·ORAL saliva collection and stabilization device in COVID-19 testing.

• OraSure’s ORAcollect®·RNA Device Included in EUA Granted to Quadrant Biosciences Inc. for COVID-19 Test

  9/24/2020

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that its ORAcollect®·RNA saliva collection device has been included in the U.S. Food and Drug Administration Emergency Use Authorization granted to Quadrant Biosciences Inc. for a COVID-19 laboratory test.

• OraSure’s ORAcollect®·RNA Device Included in EUA Granted to MiraDx Inc. for SARS-CoV-2 Test

  9/3/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its ORAcollect®·RNA (OR-100) collection device was included along with other devices in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to MiraDx Inc., a Los Angeles-based molecular genetics company. This is the fifth EUA

• OraSure Technologies to Present at Upcoming Investor Conferences

  8/27/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the following upcoming investor conferences:

• OraSure Technologies, Inc. Announces 2020 Second Quarter Financial Results and Update on COVID-19 Testing Programs

  8/5/2020

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced its financial results for the three and six months ended June 30, 2020.

• OraSure’s OMNIgene®·ORAL Device Included in EUA Granted to Clinical Reference Laboratory for Self-Collected SARS-CoV-2 Saliva Test

  7/31/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), today announced that its OMNIgene®·ORAL (OM-505) saliva collection device is included in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) granted to Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the United States, for SARS-CoV-2 testing.

• OraSure Technologies to Hold Second Quarter 2020 Earnings Conference Call on August 5th, 2020

  7/22/2020

  OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2020 second quarter financial results and certain business developments for 5:00 pm ET on Wednesday, August 5, 2020.

• Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study

  6/25/2020

  Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ:OSUR), and Alimentiv Inc. (formerly Robarts Clinical Trials) today announced they have signed a collaboration agreement for a research study on patients with Acute Severe Ulcerative Colitis (ASUC). The study, titled: “ Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis (PROTOS Study),

• OraSure’s DNA Genotek Subsidiary Unveils First In-Home Self-Collection Device for Metabolomics

  6/17/2020

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services is introducing the first and only commercially available device for in-home, self-collection of fecal samples for metabolomics.

• OraSure Technologies Receives BARDA Funding for Coronavirus Antibody ELISA Using Oral Fluid Samples

  6/10/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $629,217 contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to develop an Enzyme-Lin

• OraSure’s Oragene®•Dx included in EUA allowing at-home saliva collection for use with Phosphorus SARS-CoV-2 testThe number of EUAs utilizing OraSure’s saliva collection products continues to grow

  6/8/2020

  OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced today that Phosphorus Diagnostics, a leader in diagnostic and bioinformatic solutions for clinical next generation sequencing (NGS), was granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration

• OraSure Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares of Common Stock - June 04, 2020

  6/4/2020

  OraSure Technologies, Inc. announced the full exercise by the underwriters of their option to purchase an additional 1,200,000 shares of its common stock in connection with the Company’s previously announced offering that priced on June 2, 2020.

• OraSure Technologies, Inc. Prices Underwritten Offering of Common Stock - June 03, 2020

  6/3/2020

  OraSure Technologies, Inc. announced the pricing of an underwritten offering of 8,000,000 shares of its common stock at a price of $11.00 per share.

• OraSure Technologies, Inc. Announces Proposed Public Offering of Common Stock - Jun 01, 2020

  6/1/2020

  OraSure Technologies, Inc. announced it has commenced an underwritten public offering of 8,000,000 shares of its common stock.

• OraSure Technologies, Inc. Announces Purchase of UrSure, Inc.

  5/29/2020

  OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection and stabilization devices, and microbiome laboratory and analytical services, announced that it has entered into a definitive agreement to acquire privately owned UrSure, Inc. for cash.

• OraSure Technologies Appoints Lelio Marmora to Board of Directors

  5/29/2020

  OraSure Technologies, Inc., a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced the appointment of Lelio Marmora as a member of the Company’s Board of Directors effective June 1, 2020.

• OraSure Technologies to Present at the Jefferies 2020 Healthcare Conference

  5/26/2020

  OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, announced that Dr. Stephen S. Tang, Ph.D., President and CEO, will speak to the investment community at the Jefferies 2020 Healthcare Conference.

• OraSure’s OMNIgene®·ORAL Kit Included in EUA Granted to P23 Labs for At-Home Collection of Saliva Samples for SARS-CoV-2 Test

  5/22/2020

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that its OMNIgene®·ORAL saliva collection device was included in the U.S. Food and Drug Administration Emergency Use Authorization granted to P23 Labs.

• Diversigen Inc. Selected by Nom Nom™ as the Preferred Provider for Metagenomics and Microbiome Sequencing and Analysis Services

  5/22/2020

  Diversigen, Inc., a subsidiary of OraSure Technologies Inc., and Nom Nom™, a direct-to-consumer pet health brand, announced that Nom Nom has selected Diversigen as their preferred provider for metagenomics and microbiome sequencing and analysis services.

• OraSure Technologies to Present at the UBS Virtual Global Healthcare Conference

  5/15/2020

  OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection devices, announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the UBS Virtual Global Healthcare Conference.